Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43146 (
tumour suppressor
)
5,935
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Altered glycosylation is considered a universal cancer hallmark. Mucin-type core 2 1,6-N-acetylglucosaminyltransferase enzyme (C2GnT-M), encoded by the
GCNT3
gene, has been reported to be altered in tumours and to possess
tumour suppressor
properties. In this work, we aimed to determine the possible role of
GCNT3
gene expression as prognostic marker in colon cancer. We investigated the differential expression of
GCNT3
gene among tumour samples from stage II colon cancer patients by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Univariate and Multivariate Cox regression analyses were used to determine the correlation between
GCNT3
expression and disease-free survival. The risk of relapse in
GCNT3
low-expressing cancer patients was significantly higher than that in
GCNT3
high-expressing patients in both training (Hazard Ratio (HR) 4.26, p=0.002) and validation (HR 3.06, p=0.024) series of patients, and this association was independent of clinical factors. Additionally, qRT-PCR was used to explore the modulation of
GCNT3
expression by different antitumour drugs. Three chemotherapeutic agents with different mechanism of action (5-fluorouracil, bortezomib and paclitaxel) significantly induced
GCNT3
expression in several cancer cells, being observed the correlation between antitumour action and
GCNT3
modulation, whereas this gene was not modulated in cells that do not respond to treatment. Overall, these results indicate that low
GCNT3
expression is a promising prognostic biomarker for colon cancer that could be used to identify early-stage colon cancer patients at high risk of relapse. Additionally, our results suggest that this enzyme might also constitute a biomarker to monitor tumour response to chemotherapy in cancer patients.
...
PMID:Clinical relevance of the differential expression of the glycosyltransferase gene GCNT3 in colon cancer. 2546 7